Navigation Links
Ampio Pharmaceuticals Receives Notice of Allowance of its Two Patent Applications on the Combination of Zertane™ with Erectile Dysfunction Drugs in Canada
Date:9/28/2011

GREENWOOD VILLAGE, Colo., Sept. 28, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced that it has received notification of allowance of its two patent applications on Zertane™ combinations with erectile dysfunction (ED) drugs in Canada.  This allowance includes claims directed to the use of Zertane™ with a class of drugs called phosphodiesterase type 5 (PDE5) inhibitors commonly used for the treatment of ED to address concurrent premature ejaculation (PE) and ED. The allowed claims also include composition of matter claims, such as claims directed to a pharmaceutical composition or a kit containing Zertane™ and a PDE5 inhibitor. Similar patent applications are being prosecuted worldwide.

It has been reported that ED and PE can co-exist in up to 30% of patients. There may be patients with ED who are effectively treated with phosphodiesterase type 5 inhibitors but who may have PE.  The patented combination of PE and ED drugs addresses this substantial group of patients.

"This first allowance of these two patents in Canada is an important milestone in Ampio's strategy to continue the development of its sexual dysfunction portfolio by first obtaining strong intellectual property protection," said Don Wingerter Ampio's CEO. "We are very excited by this development as we anticipate it will help increase our growing out-licensing activity for this product line," continued Don Wingerter.

About Zertane

The active ingredient in Zertane™ is a drug that was approved for marketing as a noncontrolled analgesic in 1995. In two Phase III clinical trials, Zertane™ has proven to be an effective oral medication to treat PE in men. Premature ejaculation
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ampio Announces Positive Results From 12-Week Open Label Extension Study of Zertane™ in Patients With Premature Ejaculation.
2. Champions Oncology Reports Fiscal 2012 First Quarter Financial Results
3. Ampio Pharmaceuticals Executes License and Development Agreement with Daewoong Co. Ltd. to Commercialize Zertane™ in South Korea
4. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
5. Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertane™ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction
6. Ampio Pharmaceuticals Set to Join Russell 3000 Index
7. Ampio Pharmaceuticals, Inc. Appoints New Independent Director
8. Ampio Pharmaceuticals, Inc. to Begin Trading on the NASDAQ Capital Market
9. Ampio Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Capital Market
10. Five Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of California
11. Champions Biotechnology Exercises Option to License Proprietary Compound Based on Successful Tumorgraft™ Test Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 The Eastern ... Both established medical-device providers as well as new medical-device ... region, while simultaneously looking at ways to reduce the ... Using distributors is one of the effective means to ... devices distribution market in Eastern European and provides profiles ...
(Date:9/30/2014)... 2014 The report based on ... Share, Growth and Forecast, 2007 - 2017," elaborated by ... 20.8 billion in 2012 and is further expected to ... CAGR of 7.3% from 2012 to 2017. ... purposes, especially to prevent chronic diseases that may occur ...
(Date:9/30/2014)... In a recent study it ... of the Eldor spinal needle 25G, 103 mm appeared ... point spinal needles of the same gauge and length ... is an excellent type of regional anesthesia for many ... It is estimated that 100 million patients ...
Breaking Medicine Technology:Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4
... 2011 Actavis Group, an international generic pharmaceuticals company, ... US Food & Drug Administration to market Valacyclovir Hydrochloride ... and 1 gram, the generic equivalent of Valtrex® by ... the 12 months ending December 31, 2010, according to ...
... 2011 NephRx Corporation today announced issuance of a ... factor peptide NX002 as a potential treatment for inflammatory ... have applications in acute and chronic diseases of the ... has been shown to stimulate the growth of epithelial ...
Cached Medicine Technology:Actavis Receives Approval of Valacyclovir Hydrochloride Tablets in the U.S. 2NephRx Corp. Awarded U.S. Patent for Use of Novel Growth Factor Peptide NX002 in Inflammatory Bowel Disease 2
(Date:9/30/2014)... Randy Dotinga HealthDay Reporter ... unemployment rates climb, women tend to put the brakes on ... out to be a permanent choice, new research suggests. ... not to have a child during tough economic times. But, ... women will remain childless into their 40s and beyond. ...
(Date:9/30/2014)... Alan Mozes Health ... News) -- Colon cancer patients who are overweight or ... risk for developing a second weight-related cancer, new research ... risk of colon cancer recurrence, only the potential for ... found that colorectal cancer survivors who reported being overweight ...
(Date:9/30/2014)... R.I. [Brown University] Autism is no stranger to ... East African nation is access to clinical services, including ... diagnostic measure, for example, validated for use in Swahili, ... new study, however, researchers at Brown University and the ... approach that they implemented at two sites in the ...
(Date:9/30/2014)... A new study of 58 women conducted ... stress on metabolism after eating a high-fat meal equivalent to ... food restaurant, about 930 calories and 60 grams of fat. ... hour for 7 hours, conducting the study twice on each ... a stressful event in their lives during the previous 24 ...
(Date:9/30/2014)... Health Centers (FQHCs) granted new patient appointments to ... than other primary care practices (non-FQHCs), in addition ... of a new 10-state University of Pennsylvania study ... , Using data from a previous "secret shopper" ... found that FQHCs community health clinics that ...
Breaking Medicine News(10 mins):Health News:Recessions May Thwart a Woman's Motherhood Plans Forever: Study 2Health News:Recessions May Thwart a Woman's Motherhood Plans Forever: Study 3Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 2Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 3Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 3Health News:Medicaid and Uninsured patients obtain new patient appointments most easily at FQHCs 2
... (IADR) announces Dr. Anthony Fauci, director, National Institute of ... of Health in Bethesda, Md., USA as 2009 IADR ... the 87th General Session & Exhibition in Miami, Florida, ... Fauci became director of NIAID, where he oversees an ...
... Thirty-seven scientists from Cold Spring Harbor Laboratory (CSHL) and 20 ... issued a major challenge to the neuroscience community. At ... just-published paper, to assemble a comprehensive map of the major ... in which the genomes of many organisms, including that of ...
... a lot of a hormone needed to eliminate the excess ... the enzyme needed to activate it, researchers say. , ... found people in heart failure have less of the enzyme ... hormone made by heart muscle cells that, when active, helps ...
... Society Emphasizes A Special Calling: Knowledge ... Leadership ... A ... With a majority of its nurses nearing ... is urging its members to respond to a new calling ... National Wound, Ostomy and Continence Nurses Week, April 12 - ...
... March 31 Pacific Fertility Center is pleased to ... diagnosis (PGD) and preimplantation genetic screening (PGS). Recent ... The use of this science for such "futuristic" action ... it is used today. Pacific Fertility Center is proud ...
... The not-for-profit LENA Foundation is putting forth a ... Society of Research in Child Development (SRCD). At the ... one poster will be presented based on findings using ... SRCD is a great opportunity for our colleagues to ...
Cached Medicine News:Health News:CSHL neuroscientists propose project to comprehensively map mammalian brain circuits 2Health News:CSHL neuroscientists propose project to comprehensively map mammalian brain circuits 3Health News:CSHL neuroscientists propose project to comprehensively map mammalian brain circuits 4Health News:CSHL neuroscientists propose project to comprehensively map mammalian brain circuits 5Health News:New tests provide new insight into why patients are in heart failure 2Health News:New tests provide new insight into why patients are in heart failure 3Health News:Wound, Ostomy & Continence Nurses Society Focuses On Preparing the Next Generation of Leaders 2Health News:Wound, Ostomy & Continence Nurses Society Focuses On Preparing the Next Generation of Leaders 3Health News:PGD Technology Offers More Than Designer Babies 2Health News:PGD Technology Offers More Than Designer Babies 3Health News:PGD Technology Offers More Than Designer Babies 4Health News:Five Research Studies at International SRCD Meeting in Denver Use Technology from Boulder Foundation 2Health News:Five Research Studies at International SRCD Meeting in Denver Use Technology from Boulder Foundation 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: